New HIV drug MK-4646 put through safety check in healthy volunteers
NCT ID NCT07532304
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether a new experimental HIV drug, MK-4646, changes the levels of standard HIV medications (BIC/FTC/TAF and dolutegravir) in the blood. It involves 16 healthy volunteers and focuses on safety and drug interactions, not treatment. The results will help guide future studies in people living with HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MK-4646
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pinnacle Research Group ( Site 0001)
Anniston, Alabama, 36207, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test